Literature DB >> 25565063

Trends in imaging after diagnosis of thyroid cancer.

Jaime L Wiebel1, Mousumi Banerjee, Daniel G Muenz, Francis P Worden, Megan R Haymart.   

Abstract

BACKGROUND: The largest growth noted among differentiated thyroid cancer (DTC) diagnosis is in low-risk cancers. Trends in imaging after the diagnosis of DTC are understudied. Hypothesizing a reduction in imaging use due to rising low-risk disease, the authors evaluated postdiagnosis imaging patterns over time and patient characteristics that are associated with the likelihood of imaging.
METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, the authors identified patients diagnosed with localized, regional, or distant DTC between 1991 and 2009. Medicare claims were reviewed for use of neck ultrasound, iodine-131 (I-131) scan, or positron emission tomography (PET) scan within 3 years after diagnosis. Trends in imaging use were evaluated using regression analyses. Multivariable logistic regression was used to estimate the likelihood of imaging based on patient characteristics.
RESULTS: A total of 23,669 patients were included. Compared with patients diagnosed between 1991 and 2000, those diagnosed between 2001 and 2009 were more likely to have localized disease (P<.001) and tumors measuring <1 cm (P<.001). Use of neck ultrasound and I-131 scans increased in patients with localized disease (P ≤.001 and P = .003, respectively), regional disease (P<.001 and P<.001, respectively), and distant metastasis (P = .001 and P = .015, respectively). Patients diagnosed after 2000 were more likely to undergo neck ultrasound (odds ratio, 2.15; 95% confidence interval, 2.02-2.28) and I-131 scan (odds ratio, 1.44; 95% confidence interval, 1.35-1.54). Compared with 1996 through 2004, PET scan use from 2005 to 2009 increased 32.4-fold (P≤.001) in patients with localized disease, 13.1-fold (P<.001) in patients with regional disease, and 33.4-fold (P<.001) in patients with distant DTC.
CONCLUSIONS: Despite an increase in the diagnosis of low-risk disease, the use of postdiagnosis imaging increased among patients with all stages of disease. The largest growth observed was in the use of PET after 2004.
© 2015 American Cancer Society.

Entities:  

Keywords:  differentiated thyroid cancer; neck ultrasound; positron emission tomography (PET) scan; radioiodine scan; surveillance imaging

Mesh:

Year:  2015        PMID: 25565063      PMCID: PMC4409471          DOI: 10.1002/cncr.29210

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Pacini; M G Castagna; L Brilli; G Pentheroudakis
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

2.  Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.

Authors:  Pedro Weslley Rosario; Mariana de Souza Furtado; Augusto Flávio Campos Mineiro Filho; Rafaela Xavier Lacerda; Maria Regina Calsolari
Journal:  Thyroid       Date:  2012-10-10       Impact factor: 6.568

3.  Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.

Authors:  Michaela A Dinan; Lesley H Curtis; William R Carpenter; Andrea K Biddle; Amy P Abernethy; Edward F Patz; Kevin A Schulman; Morris Weinberger
Journal:  Radiology       Date:  2013-02-15       Impact factor: 11.105

4.  Physician follow-up and observation of guidelines in the post treatment surveillance of colorectal cancer.

Authors:  Gabriela M Vargas; Kristin M Sheffield; Abhishek D Parmar; Yimei Han; Kimberly M Brown; Taylor S Riall
Journal:  Surgery       Date:  2013-08       Impact factor: 3.982

5.  Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?

Authors:  Ernest L Mazzaferri; Richard T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

6.  Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010.

Authors:  Rebecca Smith-Bindman; Diana L Miglioretti; Eric Johnson; Choonsik Lee; Heather Spencer Feigelson; Michael Flynn; Robert T Greenlee; Randell L Kruger; Mark C Hornbrook; Douglas Roblin; Leif I Solberg; Nicholas Vanneman; Sheila Weinmann; Andrew E Williams
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

7.  Radiation exposure and cost influence physician medical image decision making: a randomized controlled trial.

Authors:  Ronald W Gimbel; Paul Fontelo; Mark B Stephens; Cara H Olsen; Christopher Bunt; Christy J W Ledford; Cynthia A Loveland Cook; Fang Liu; Harry B Burke
Journal:  Med Care       Date:  2013-07       Impact factor: 2.983

8.  Thyroid carcinoma uptake of 18F-fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy.

Authors:  Kimberly M Creach; Brian Nussenbaum; Barry A Siegel; Perry W Grigsby
Journal:  Am J Otolaryngol       Date:  2012-10-23       Impact factor: 1.808

9.  Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.

Authors:  K Dennis; J H Hay; D C Wilson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-09-01       Impact factor: 4.126

10.  The increasing incidence of thyroid cancer: the influence of access to care.

Authors:  Luc G T Morris; Andrew G Sikora; Tor D Tosteson; Louise Davies
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

View more
  9 in total

1.  Worry in Thyroid Cancer Survivors with a Favorable Prognosis.

Authors:  Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart
Journal:  Thyroid       Date:  2019-07-25       Impact factor: 6.568

2.  Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer.

Authors:  Jaime L Wiebel; Nazanene H Esfandiari; Maria Papaleontiou; Francis P Worden; Megan R Haymart
Journal:  Thyroid       Date:  2015-08-03       Impact factor: 6.568

3.  The Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Biochemical Recurrence and Negative Whole-Body Radioiodine Scintigraphy and Evaluation of the Possible Role of a Limited Regional Scan.

Authors:  Manish Ora; Aftab Hasan Nazar; Prasanta Kumar Pradhan; Prabhakar Mishra; Sukanta Barai; Amitabh Arya; Manish Dixit; Ashutosh Parashar; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2020-07-01

4.  Cost-effectiveness analysis of papillary thyroid cancer surveillance.

Authors:  Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

5.  Physician Confidence in Neck Ultrasonography for Surveillance of Differentiated Thyroid Cancer Recurrence.

Authors:  Kevin J Kovatch; David Reyes-Gastelum; Jennifer A Sipos; Elaine M Caoili; Ann S Hamilton; Kevin C Ward; Megan R Haymart
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-12-23       Impact factor: 6.223

6.  Role of Patient Maximizing-Minimizing Preferences in Thyroid Cancer Surveillance.

Authors:  Joshua M Evron; David Reyes-Gastelum; Mousumi Banerjee; Laura D Scherer; Lauren P Wallner; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Brian J Zikmund-Fisher; Megan R Haymart
Journal:  J Clin Oncol       Date:  2019-10-01       Impact factor: 50.717

7.  Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.

Authors:  Johann-Martin Hempel; Roman Kloeckner; Sandra Krick; Daniel Pinto Dos Santos; Simin Schadmand-Fischer; Patrick Boeßert; Sotirios Bisdas; Matthias M Weber; Christian Fottner; Thomas J Musholt; Mathias Schreckenberger; Matthias Miederer
Journal:  Cancer Imaging       Date:  2016-11-03       Impact factor: 3.909

8.  Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence.

Authors:  Mousumi Banerjee; Jaime L Wiebel; Cui Guo; Brittany Gay; Megan R Haymart
Journal:  BMJ       Date:  2016-07-20

9.  Ions doped melanin nanoparticle as a multiple imaging agent.

Authors:  Shin-Woo Ha; Hee-Sang Cho; Young Il Yoon; Moon-Sun Jang; Kwan Soo Hong; Emmanuel Hui; Jung Hee Lee; Tae-Jong Yoon
Journal:  J Nanobiotechnology       Date:  2017-10-10       Impact factor: 10.435

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.